Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries

Hongmei Zeng 1, Wanqing Chen 2, Rongshou Zheng 1, Siwei Zhang 1, John S Ji 3, Xiaonong Zou 1, Changfa Xia 1, Kexin Sun 1, Zhixun Yang 1, He Li 1, Ning Wang 4, Renqiang Han 5, Shuzheng Liu 6, Huizhang Li 7, Huijuan Mu 8, Yutong He 9, Yanjun Xu 10, Zhentao Fu 11, Yan Zhou 12, Jie Jiang 13, Yanlei Yang 14, Jianguo Chen 15, Kuangrong Wei 16, Dongmei Fan 17, Jian Wang 18, Fangxian Fu 19, Deli Zhao 20, Guohui Song 21, Jianshun Chen 22, Chunxiao Jiang 23, Xin Zhou 24, Xiaoping Gu 25, Feng Jin 26, Qilong Li 27, Yanhua Li 28, Tonghao Wu 29, Chunhua Yan 30, Jianmei Dong 31, Zhaolai Hua 32, Peter Baade 33, Freddie Bray 34, Ahmedin Jemal 35, Xue Qin Yu 36, Jie He 37
Affiliations Expand
PMID: 29653628 DOI: 10.1016/S2214-109X(18)30127-X
Free article

Abstract

Background: From 2003 to 2005, standardised 5-year cancer survival in China was much lower than in developed countries and varied substantially by geographical area. Monitoring population-level cancer survival is crucial to the understanding of the overall effectiveness of cancer care. We therefore aimed to investigate survival statistics for people with cancer in China between 2003 and 2015.

Methods: We used population-based data from 17 cancer registries in China. Data for the study population was submitted by the end of July 31, 2016, with follow-up data on vital status obtained on Dec 31, 2015. We used anonymised, individual cancer registration records of patients (aged 0-99 years) diagnosed with primary, invasive cancers from 2003 to 2013. Patients eligible for inclusion had data for demographic characteristics, date of diagnosis, anatomical site, morphology, behaviour code, vital status, and last date of contact. We analysed 5-year relative survival by sex, age, and geographical area, for all cancers combined and 26 different cancer types, between 2003 and 2015. We stratified survival estimates by calendar period (2003-05, 2006-08, 2009-11, and 2012-15).

Findings: There were 678 842 records of patients with invasive cancer who were diagnosed between 2003 and 2013. Of these records, 659 732 (97·2%) were eligible for inclusion in the final analyses. From 2003-05 to 2012-15, age-standardised 5-year relative survival increased substantially for all cancers combined, for both male and female patients, from 30·9% (95% CI 30·6-31·2) to 40·5% (40·3-40·7). Age-standardised 5-year relative survival also increased for most cancer types, including cancers of the uterus (average change per calendar period 5·5% [95% CI 2·5-8·5]), thyroid (5·4% [3·2-7·6]), cervix (4·5% [2·9-6·2]), and bone (3·2% [2·1-4·4]). In 2012-15, age-standardised 5-year survival for all patients with cancer was higher in urban areas (46·7%, 95% CI 46·5-47·0) than in rural areas (33·6%, 33·3-33·9), except for patients with oesophageal or cervical cancer; but improvements in survival were greater for patients residing in rural areas than in urban areas. Relative survival decreased with increasing age. The increasing trends in survival were consistent with the upward trends of medical expenditure of the country during the period studied.

Interpretation: There was a marked overall increase in cancer survival from 2003 to 2015 in the population covered by these cancer registries in China, possibly reflecting advances in the quality of cancer care in these areas. The survival gap between urban and rural areas narrowed over time, although geographical differences in cancer survival remained. Insight into these trends will help prioritise areas that need increased cancer care.

Funding: National Key R&D Program of China, PUMC Youth Fund and the Fundamental Research Funds for the Central Universities, and Major State Basic Innovation Program of the Chinese Academy of Medical Sciences.

PubMed Disclaimer

Similar articles

  • Italian cancer figures–Report 2015: The burden of rare cancers in Italy.

    AIRTUM Working Group; Busco S, Buzzoni C, Mallone S, Trama A, Castaing M, Bella F, Amodio R, Bizzoco S, Cassetti T, Cirilli C, Cusimano R, De Angelis R, Fusco M, Gatta G, Gennaro V, Giacomin A, Giorgi Rossi P, Mangone L, Mannino S, Rossi S, Pierannunzio D, Tavilla A, Tognazzo S, Tumino R, Vicentini M, Vitale MF, Crocetti E, Dal Maso L.Epidemiol Prev. 2016 Jan-Feb;40(1 Suppl 2):1-120. doi: 10.19191/EP16.1S2.P001.035.PMID: 26951748
  • Changing geographical patterns and trends in cancer incidence in children and adolescents in Europe, 1991-2010 (Automated Childhood Cancer Information System): a population-based study.

    Steliarova-Foucher E, Fidler MM, Colombet M, Lacour B, Kaatsch P, Piñeros M, Soerjomataram I, Bray F, Coebergh JW, Peris-Bonet R, Stiller CA; ACCIS contributors.Lancet Oncol. 2018 Sep;19(9):1159-1169. doi: 10.1016/S1470-2045(18)30423-6. Epub 2018 Aug 8.PMID: 30098952 Free PMC article.
  • Italian cancer figures, report 2012: Cancer in children and adolescents.

    AIRTUM Working Group; CCM; AIEOP Working Group.Epidemiol Prev. 2013 Jan-Feb;37(1 Suppl 1):1-225.PMID: 23585445 English, Italian.
  • Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2).

    Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang XS, Bannon F, Ahn JV, Johnson CJ, Bonaventure A, Marcos-Gragera R, Stiller C, Azevedo e Silva G, Chen WQ, Ogunbiyi OJ, Rachet B, Soeberg MJ, You H, Matsuda T, Bielska-Lasota M, Storm H, Tucker TC, Coleman MP; CONCORD Working Group.Lancet. 2015 Mar 14;385(9972):977-1010. doi: 10.1016/S0140-6736(14)62038-9. Epub 2014 Nov 26.PMID: 25467588 Free PMC article.
  • [Methodology for survival assessment of cancer patients using population-based cancer registration data].

    Tang H, Jiang X, Lou J, Chen T.Zhejiang Da Xue Xue Bao Yi Xue Ban. 2018 Jan 25;47(1):104-109. doi: 10.3785/j.issn.1008-9292.2018.02.15.PMID: 30146819 Free PMC article. Review. Chinese.
See all similar articles

Cited by

  • Exploring stroke risk and prevention in China: insights from an outlier.

    Lin X, Wang H, Rong X, Huang R, Peng Y.Aging (Albany NY). 2021 Jun 4;13(11):15659-15673. doi: 10.18632/aging.203096. Epub 2021 Jun 4.PMID: 34086602 Free PMC article. Review.
  • Human esophageal cancer stem-like cells escape the cytotoxicity of natural killer cells via down-regulation of ULBP-1.

    Tang B, Guo M, Zhai Y, Zhang K, Ni K, Zhang Y, Huang L.J Transl Med. 2024 Aug 5;22(1):737. doi: 10.1186/s12967-024-05549-1.PMID: 39103915 Free PMC article.
  • Assessment of national reimbursement anticancer medications availability in China: based on a medical institution perspective.

    Meng W, Yang S, Wang Z, Xie J, Jiang R.BMC Public Health. 2024 Aug 21;24(1):2268. doi: 10.1186/s12889-024-19786-y.PMID: 39169407 Free PMC article.
  • Oncological characteristics, treatments and prognostic outcomes in MMR-deficient colorectal cancer.

    Fan WX, Su F, Zhang Y, Zhang XL, Du YY, Gao YJ, Li WL, Hu WQ, Zhao J.Biomark Res. 2024 Aug 26;12(1):89. doi: 10.1186/s40364-024-00640-7.PMID: 39183366 Free PMC article. Review.
  • Health economic evaluation on population-based Helicobacter pylori eradication and endoscopic screening for gastric cancer prevention.

    Hu Z, Liu Z, Li W, You W, Pan K.Chin J Cancer Res. 2023 Dec 30;35(6):595-605. doi: 10.21147/j.issn.1000-9604.2023.06.04.PMID: 38204445 Free PMC article.

Leave a Reply

Your email address will not be published. Required fields are marked *